C4 Therapeutics reported third-quarter 2026 results alongside updates on its cemsidomide clinical program, which is being developed for multiple myeloma. The company’s near-term focus is completing a Phase 2 trial in patients with later-line disease and advancing studies that combine cemsidomide with immune-based treatments.
Several key clinical readouts are expected in 2027. The updates also include early biomarker findings, but no clinical response results from the cemsidomide–elranatamab study were reported.
Key details
-
Phase 2 MOMENTUM trial: The study of cemsidomide with dexamethasone in later-line multiple myeloma remains on track to complete enrollment in the first quarter of 2027. Initial investigator-assessed overall response rate data are expected in the second half of 2027.
-
Cemsidomide plus elranatamab: In this Phase 1b study for patients with relapsed or refractory multiple myeloma, a safety review committee cleared the 75-microgram cemsidomide dose to proceed. The trial has moved into a safety dose-escalation cohort at 100 micrograms and an expansion cohort at 75 micrograms. Data from all evaluated cohorts are expected in mid-2027.
-
Early biomarker findings: Data presented at the International Myeloma Society meeting in September showed T-cell activation in the Phase 1 cemsidomide-and-dexamethasone study. Biomarker results from the first two patients in the elranatamab combination study also showed T-cell activation and expansion, with findings consistent with reduced T-cell exhaustion. These are early biological observations, not evidence of the combination’s clinical effectiveness.
-
Additional combination study: C4 Therapeutics said a Phase 1b trial combining cemsidomide with approved standard-of-care multiple myeloma therapies is on track to begin in the first half of 2027.
-
Upcoming scientific presentation: The company plans to present the design of its cemsidomide–elranatamab Phase 1b study at the American Society of Hematology annual meeting in December. The presentation is a trial-design update, not a new results announcement.
What changes for investors
The announced milestones put several cemsidomide data points on the 2027 calendar, including response data from the Phase 2 MOMENTUM study and results from the elranatamab combination cohorts. The program is also being tested in combinations intended for different stages of multiple myeloma treatment. The reported biomarker findings support the company’s rationale for pairing cemsidomide with immune-based therapies, but the announcement provides no clinical response results from the elranatamab study.